Theravance Biopharma Inc
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| · · | |||
|---|---|---|---|
| · PART I · | |||
| Item 1. | Business | | 4 |
| Item 1A. | Risk Factors | | 20 |
| Item 1B. | Unresolved Staff Comments | | 52 |
| Item 1C. | Cybersecurity | | 52 |
| Item 2. | Properties | | 54 |
| Item 3. | Legal Proceedings | | 54 |
| Item 4. | Mine Safety Disclosures | | 55 |
| | PART II | | |
| Item 5. | Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | | 56 |
| Item 6. | [Reserved] | | 57 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 58 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | | 65 |
| Item 8. | Financial Statements and Supplementary Data | | 65 |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | | 65 |
| Item 9A. | Controls and Procedures | | 65 |
| Item 9B. | Other Information | | 66 |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | | 66 |
| | PART III | | |
| Item 10. | Directors, Executive Officers and Corporate Governance | | 67 |
| Item 11. | Executive Compensation | | 67 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | | 67 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | | 67 |
| Item 14. | Principal Accountant Fees and Services | | 67 |
| | PART IV | | |
| Item 15. | Exhibits and Financial Statement Schedules | | 68 |
| Exhibit Index | | 69 | |
| Signatures | | 73 | |
Special Note regarding Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements involve risks, uncertainties and assumptions. All statements in this Annual Report on Form 10-K, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, intentions, designs, expectations, and objectives are forward-looking statements. The words “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “designed,” “developed,” “drive,” “estimate,” “expect,” “forecast,” “goal,” “indicate,” “intend,” “may,” “mission,” “opportunities,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “represent,” “seek,” “suggest,” “should,” “target,” “will,” “would,” and similar expressions (including the negatives thereof) are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. These statements reflect our current views with respect to future events or our future financial performance, are based on assumptions, and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward-looking statements and the assumptions underlying our forward-looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and objectives disclosed in the forward-looking statements that we make. Factors that we believe could cause actual results or events to differ materially from our forward-looking statements include, but are not limited to, those discussed in “Risk Factors,” in Item 1A, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 and elsewhere in this Annual Report on Form 10-K. Our forward-looking statements in this Annual Report on Form 10-K are based on current expectations, and we do not assume any obligation to update any forward-looking statements for any reason, even if new information becomes available in the future. When used in this report, all references to “Theravance Biopharma”, the “Company”, or “we” and other similar pronouns refer to Theravance Biopharma, Inc. collectively with its subsidiaries.
PART I
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.